The Canadian pharmaceutical company SaNOtize Research & Development Corp., (SaNOtize), and Glenmark Pharmaceuticals Limited (Glenmark),  announced earlier this month the successful outcomes of a nasal spray in its Phase 3 clinical trials and now approved by India’s drug regulator as a treatment for adult patients with COVID-19 who have a risk of progression of the disease.